MedTrace Logo

Clopidogrel Preventive Effect Based on CYP2C19 Genotype in Ischemic Stroke

NCT04072705 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2927

Last updated 2023-09-25

No results posted yet for this study

Summary

The hypothesis of this study is that "the poor metabolizer or intermediate metabolizer of the cytochrome P450 2C19 genotype in patients with acute ischemic stroke is associated with increased risk of composite cardiovascular events (recurrent stroke, myocardial infarction, cardiovascular death) compared to those who of extensive metabolizer of the cytochrome P450 2C19 genotype".

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

General principles of care and judgement of researcher

Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.

Sponsors & Collaborators

  • SAMJIN PHARM

    collaborator UNKNOWN

  • Gangnam Severance Hospital

    lead OTHER

Principal Investigators

  • KyungYul Lee · Gangnam Severance Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-20
Primary Completion
2023-01-11
Completion
2023-07-07
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04072705 on ClinicalTrials.gov